NASDAQ:NRIX Nurix Therapeutics Q2 2024 Earnings Report $25.52 +0.42 (+1.67%) Closing price 04:00 PM EasternExtended Trading$25.54 +0.02 (+0.08%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nurix Therapeutics EPS ResultsActual EPS-$0.71Consensus EPS -$0.63Beat/MissMissed by -$0.08One Year Ago EPSN/ANurix Therapeutics Revenue ResultsActual Revenue$12.09 millionExpected Revenue$19.35 millionBeat/MissMissed by -$7.26 millionYoY Revenue GrowthN/ANurix Therapeutics Announcement DetailsQuarterQ2 2024Date7/11/2024TimeTASConference Call DateThursday, July 11, 2024Conference Call Time4:00PM ETUpcoming EarningsNurix Therapeutics' Q3 2026 earnings is estimated for Thursday, October 8, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nurix Therapeutics Earnings HeadlinesNurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comNurix Therapeutics (NASDAQ:NRIX) Downgraded by Wall Street Zen to "Sell"September 5, 2026 | americanbankingnews.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.September 14 at 1:00 AM | Traders Agency (Ad)Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Nurix Therapeutics (NRIX)September 2, 2026 | theglobeandmail.comNurix Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 1, 2026 | globenewswire.comNurix Advances NX-5948 Combo Trial in B-Cell Cancers, Setting Up Key Catalyst for NRIXAugust 28, 2026 | tipranks.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX) is a biopharmaceutical company focused on developing medicines that regulate the body’s natural protein-disposal systems to treat cancer and other serious diseases. The company’s approach centers on targeted protein modulation, including the use of small molecules to promote the degradation of disease-causing proteins or alter the activity of proteins involved in immune responses. Nurix’s technology platform is built around E3 ligases, enzymes that help determine which proteins are marked for destruction inside cells. Using this platform, the company develops targeted protein degraders and molecular glues designed to eliminate or modify selected proteins that may contribute to cancer. Its pipeline has included oral investigational therapies targeting proteins involved in B-cell malignancies and immune-cell regulation, including BTK and Cbl-b. The company’s research and development programs have included NX-5948, an orally administered BTK degrader being studied in B-cell cancers, and NX-1607, an investigational Cbl-b inhibitor intended to modulate immune-cell activity. Nurix has also pursued discovery and development collaborations with larger pharmaceutical companies, including Gilead Sciences, to apply its targeted protein degradation technology to additional therapeutic programs. Nurix Therapeutics was founded in 2009 and is headquartered in San Francisco, California. Its operations are primarily focused on drug discovery and clinical development, with programs intended for patients in international oncology and immunology markets. The company’s common stock trades on the Nasdaq under the symbol NRIX.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed EarningsMarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundThe End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
